HEADER APOPTOSIS 14-DEC-17 6BW2 TITLE MCL-1 COMPLEXED WITH SMALL MOLECULES COMPND MOL_ID: 1; COMPND 2 MOLECULE: INDUCED MYELOID LEUKEMIA CELL DIFFERENTIATION PROTEIN MCL- COMPND 3 1; COMPND 4 CHAIN: A, B, C, D; COMPND 5 SYNONYM: BCL-2-LIKE PROTEIN 3,BCL2-L-3,BCL-2-RELATED PROTEIN COMPND 6 EAT/MCL1,MCL1/EAT; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: MCL1, BCL2L3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS MCL-1 INHIBITOR, CANCER, STRUCTURE-BASED DESIGN, DRUG DISCOVERY, KEYWDS 2 APOPTOSIS EXPDTA X-RAY DIFFRACTION AUTHOR B.ZHAO REVDAT 5 04-OCT-23 6BW2 1 REMARK REVDAT 4 04-DEC-19 6BW2 1 REMARK REVDAT 3 04-APR-18 6BW2 1 JRNL REVDAT 2 21-MAR-18 6BW2 1 JRNL REVDAT 1 31-JAN-18 6BW2 0 JRNL AUTH S.SHAW,Z.BIAN,B.ZHAO,J.C.TARR,N.VEERASAMY,K.O.JEON,J.BELMAR, JRNL AUTH 2 A.L.ARNOLD,S.A.FOGARTY,E.PERRY,J.L.SENSINTAFFAR,D.V.CAMPER, JRNL AUTH 3 O.W.ROSSANESE,T.LEE,E.T.OLEJNICZAK,S.W.FESIK JRNL TITL OPTIMIZATION OF POTENT AND SELECTIVE TRICYCLIC INDOLE JRNL TITL 2 DIAZEPINONE MYELOID CELL LEUKEMIA-1 INHIBITORS USING JRNL TITL 3 STRUCTURE-BASED DESIGN. JRNL REF J. MED. CHEM. V. 61 2410 2018 JRNL REFN ISSN 1520-4804 JRNL PMID 29323899 JRNL DOI 10.1021/ACS.JMEDCHEM.7B01155 REMARK 2 REMARK 2 RESOLUTION. 2.75 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (1.11.1_2575: ???) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.75 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 29.73 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 3.380 REMARK 3 COMPLETENESS FOR RANGE (%) : 96.8 REMARK 3 NUMBER OF REFLECTIONS : 25203 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.247 REMARK 3 R VALUE (WORKING SET) : 0.245 REMARK 3 FREE R VALUE : 0.262 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.880 REMARK 3 FREE R VALUE TEST SET COUNT : 1207 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 26.1390 - 5.7032 0.95 2789 139 0.2591 0.2441 REMARK 3 2 5.7032 - 4.5345 0.95 2758 145 0.2293 0.2615 REMARK 3 3 4.5345 - 3.9636 0.95 2728 126 0.2185 0.2410 REMARK 3 4 3.9636 - 3.6022 0.95 2731 125 0.2363 0.2864 REMARK 3 5 3.6022 - 3.3446 0.94 2722 120 0.2435 0.2755 REMARK 3 6 3.3446 - 3.1477 0.92 2659 136 0.2554 0.2743 REMARK 3 7 3.1477 - 2.9903 0.90 2550 126 0.2647 0.2439 REMARK 3 8 2.9903 - 2.8603 0.87 2549 141 0.2703 0.2821 REMARK 3 9 2.8603 - 2.7503 0.87 2501 139 0.2829 0.3334 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : NULL REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 27.240 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.003 4995 REMARK 3 ANGLE : 0.694 6767 REMARK 3 CHIRALITY : 0.037 722 REMARK 3 PLANARITY : 0.003 851 REMARK 3 DIHEDRAL : 11.658 2862 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 1 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: ALL REMARK 3 ORIGIN FOR THE GROUP (A): 50.5270 -33.2684 22.2962 REMARK 3 T TENSOR REMARK 3 T11: 0.7039 T22: 0.6525 REMARK 3 T33: 0.4228 T12: 0.0487 REMARK 3 T13: -0.0047 T23: -0.0297 REMARK 3 L TENSOR REMARK 3 L11: 0.2497 L22: 0.2822 REMARK 3 L33: 0.1603 L12: -0.0232 REMARK 3 L13: 0.0116 L23: 0.0551 REMARK 3 S TENSOR REMARK 3 S11: 0.0502 S12: 0.0136 S13: -0.0680 REMARK 3 S21: -0.0961 S22: -0.0561 S23: 0.0121 REMARK 3 S31: 0.0576 S32: 0.0279 S33: 0.0000 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6BW2 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 02-JAN-18. REMARK 100 THE DEPOSITION ID IS D_1000231685. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 10-JUN-15 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 21-ID-F REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RAYONIX MX300-HS REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 25203 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.750 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 96.7 REMARK 200 DATA REDUNDANCY : 4.100 REMARK 200 R MERGE (I) : 0.08800 REMARK 200 R SYM (I) : 0.07600 REMARK 200 FOR THE DATA SET : 11.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.75 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.86 REMARK 200 COMPLETENESS FOR SHELL (%) : 87.0 REMARK 200 DATA REDUNDANCY IN SHELL : 1.90 REMARK 200 R MERGE FOR SHELL (I) : 0.36400 REMARK 200 R SYM FOR SHELL (I) : 0.71900 REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 4ZBF REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 65.29 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.54 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20%-30% PEG 3350, MAGNESIUM CHLORIDE, REMARK 280 BIS-TRIS, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 67.18450 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3, 4 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 4 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ALA A 170 REMARK 465 ASP A 171 REMARK 465 GLU A 322 REMARK 465 ASP A 323 REMARK 465 LEU A 324 REMARK 465 GLU A 325 REMARK 465 GLY A 326 REMARK 465 GLY A 327 REMARK 465 ALA B 170 REMARK 465 ASP B 171 REMARK 465 ASP B 172 REMARK 465 VAL B 321 REMARK 465 GLU B 322 REMARK 465 ASP B 323 REMARK 465 LEU B 324 REMARK 465 GLU B 325 REMARK 465 GLY B 326 REMARK 465 GLY B 327 REMARK 465 ALA C 170 REMARK 465 ASP C 171 REMARK 465 VAL C 321 REMARK 465 GLU C 322 REMARK 465 ASP C 323 REMARK 465 LEU C 324 REMARK 465 GLU C 325 REMARK 465 GLY C 326 REMARK 465 GLY C 327 REMARK 465 ALA D 170 REMARK 465 ASP D 171 REMARK 465 ASP D 172 REMARK 465 VAL D 321 REMARK 465 GLU D 322 REMARK 465 ASP D 323 REMARK 465 LEU D 324 REMARK 465 GLU D 325 REMARK 465 GLY D 326 REMARK 465 GLY D 327 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 180 CG CD OE1 OE2 REMARK 470 LYS A 194 CG CD CE NZ REMARK 470 LYS A 197 CG CD CE NZ REMARK 470 PRO A 198 CG CD REMARK 470 MET A 199 CG SD CE REMARK 470 ARG A 201 CG CD NE CZ NH1 NH2 REMARK 470 THR A 226 OG1 CG2 REMARK 470 LYS A 279 NZ REMARK 470 LYS A 308 CE NZ REMARK 470 GLU B 180 CG CD OE1 OE2 REMARK 470 LYS B 194 CG CD CE NZ REMARK 470 PRO B 198 CG CD REMARK 470 MET B 199 CG SD CE REMARK 470 SER B 202 OG REMARK 470 LYS B 234 CD CE NZ REMARK 470 ILE B 237 CG1 CG2 CD1 REMARK 470 LYS B 244 CE NZ REMARK 470 ASP C 172 CG OD1 OD2 REMARK 470 ARG C 176 CG CD NE CZ NH1 NH2 REMARK 470 ARG C 184 CG CD NE CZ NH1 NH2 REMARK 470 LYS C 197 CG CD CE NZ REMARK 470 MET C 199 SD CE REMARK 470 GLU C 211 CG CD OE1 OE2 REMARK 470 VAL C 220 CG1 CG2 REMARK 470 ARG C 222 CG CD NE CZ NH1 NH2 REMARK 470 LYS C 244 CE NZ REMARK 470 ILE C 251 CD1 REMARK 470 LYS C 308 CG CD CE NZ REMARK 470 ARG C 310 CG CD NE CZ NH1 NH2 REMARK 470 GLU D 173 CG CD OE1 OE2 REMARK 470 GLN D 177 CG CD OE1 NE2 REMARK 470 ILE D 181 CG1 CG2 CD1 REMARK 470 ASP D 195 OD2 REMARK 470 MET D 199 SD CE REMARK 470 SER D 202 OG REMARK 470 LEU D 210 CD1 CD2 REMARK 470 LYS D 244 CD CE NZ REMARK 470 VAL D 258 CG1 CG2 REMARK 470 LYS D 279 CG CD CE NZ REMARK 470 ARG D 310 CG CD NE CZ NH1 NH2 REMARK 470 GLU D 317 CG CD OE1 OE2 REMARK 470 PHE D 319 CG CD1 CD2 CE1 CE2 CZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 195 131.93 44.77 REMARK 500 THR A 196 -133.92 -80.01 REMARK 500 LYS A 197 153.02 65.66 REMARK 500 MET A 199 44.93 -88.60 REMARK 500 LYS A 238 -40.46 -133.17 REMARK 500 PHE A 319 48.09 -101.41 REMARK 500 ASP B 195 105.16 62.24 REMARK 500 ASN B 239 -166.58 -162.07 REMARK 500 PHE B 319 45.78 -100.80 REMARK 500 GLU C 173 -38.77 -141.16 REMARK 500 ASP C 195 109.76 -47.53 REMARK 500 THR C 196 -125.03 -74.00 REMARK 500 LYS C 197 152.89 67.16 REMARK 500 ASP C 236 70.01 50.08 REMARK 500 PHE C 319 48.77 -102.41 REMARK 500 ASP D 195 110.14 33.37 REMARK 500 THR D 196 -138.65 -74.32 REMARK 500 LYS D 197 150.17 60.59 REMARK 500 GLN D 283 56.57 -140.36 REMARK 500 PHE D 319 44.59 -106.14 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ECY A 400 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ECY B 400 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ECY C 400 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ECY D 400 DBREF 6BW2 A 172 327 UNP Q07820 MCL1_HUMAN 172 327 DBREF 6BW2 B 172 327 UNP Q07820 MCL1_HUMAN 172 327 DBREF 6BW2 C 172 327 UNP Q07820 MCL1_HUMAN 172 327 DBREF 6BW2 D 172 327 UNP Q07820 MCL1_HUMAN 172 327 SEQADV 6BW2 ALA A 170 UNP Q07820 EXPRESSION TAG SEQADV 6BW2 ASP A 171 UNP Q07820 EXPRESSION TAG SEQADV 6BW2 ALA B 170 UNP Q07820 EXPRESSION TAG SEQADV 6BW2 ASP B 171 UNP Q07820 EXPRESSION TAG SEQADV 6BW2 ALA C 170 UNP Q07820 EXPRESSION TAG SEQADV 6BW2 ASP C 171 UNP Q07820 EXPRESSION TAG SEQADV 6BW2 ALA D 170 UNP Q07820 EXPRESSION TAG SEQADV 6BW2 ASP D 171 UNP Q07820 EXPRESSION TAG SEQRES 1 A 158 ALA ASP ASP GLU LEU TYR ARG GLN SER LEU GLU ILE ILE SEQRES 2 A 158 SER ARG TYR LEU ARG GLU GLN ALA THR GLY ALA LYS ASP SEQRES 3 A 158 THR LYS PRO MET GLY ARG SER GLY ALA THR SER ARG LYS SEQRES 4 A 158 ALA LEU GLU THR LEU ARG ARG VAL GLY ASP GLY VAL GLN SEQRES 5 A 158 ARG ASN HIS GLU THR ALA PHE GLN GLY MET LEU ARG LYS SEQRES 6 A 158 LEU ASP ILE LYS ASN GLU ASP ASP VAL LYS SER LEU SER SEQRES 7 A 158 ARG VAL MET ILE HIS VAL PHE SER ASP GLY VAL THR ASN SEQRES 8 A 158 TRP GLY ARG ILE VAL THR LEU ILE SER PHE GLY ALA PHE SEQRES 9 A 158 VAL ALA LYS HIS LEU LYS THR ILE ASN GLN GLU SER CYS SEQRES 10 A 158 ILE GLU PRO LEU ALA GLU SER ILE THR ASP VAL LEU VAL SEQRES 11 A 158 ARG THR LYS ARG ASP TRP LEU VAL LYS GLN ARG GLY TRP SEQRES 12 A 158 ASP GLY PHE VAL GLU PHE PHE HIS VAL GLU ASP LEU GLU SEQRES 13 A 158 GLY GLY SEQRES 1 B 158 ALA ASP ASP GLU LEU TYR ARG GLN SER LEU GLU ILE ILE SEQRES 2 B 158 SER ARG TYR LEU ARG GLU GLN ALA THR GLY ALA LYS ASP SEQRES 3 B 158 THR LYS PRO MET GLY ARG SER GLY ALA THR SER ARG LYS SEQRES 4 B 158 ALA LEU GLU THR LEU ARG ARG VAL GLY ASP GLY VAL GLN SEQRES 5 B 158 ARG ASN HIS GLU THR ALA PHE GLN GLY MET LEU ARG LYS SEQRES 6 B 158 LEU ASP ILE LYS ASN GLU ASP ASP VAL LYS SER LEU SER SEQRES 7 B 158 ARG VAL MET ILE HIS VAL PHE SER ASP GLY VAL THR ASN SEQRES 8 B 158 TRP GLY ARG ILE VAL THR LEU ILE SER PHE GLY ALA PHE SEQRES 9 B 158 VAL ALA LYS HIS LEU LYS THR ILE ASN GLN GLU SER CYS SEQRES 10 B 158 ILE GLU PRO LEU ALA GLU SER ILE THR ASP VAL LEU VAL SEQRES 11 B 158 ARG THR LYS ARG ASP TRP LEU VAL LYS GLN ARG GLY TRP SEQRES 12 B 158 ASP GLY PHE VAL GLU PHE PHE HIS VAL GLU ASP LEU GLU SEQRES 13 B 158 GLY GLY SEQRES 1 C 158 ALA ASP ASP GLU LEU TYR ARG GLN SER LEU GLU ILE ILE SEQRES 2 C 158 SER ARG TYR LEU ARG GLU GLN ALA THR GLY ALA LYS ASP SEQRES 3 C 158 THR LYS PRO MET GLY ARG SER GLY ALA THR SER ARG LYS SEQRES 4 C 158 ALA LEU GLU THR LEU ARG ARG VAL GLY ASP GLY VAL GLN SEQRES 5 C 158 ARG ASN HIS GLU THR ALA PHE GLN GLY MET LEU ARG LYS SEQRES 6 C 158 LEU ASP ILE LYS ASN GLU ASP ASP VAL LYS SER LEU SER SEQRES 7 C 158 ARG VAL MET ILE HIS VAL PHE SER ASP GLY VAL THR ASN SEQRES 8 C 158 TRP GLY ARG ILE VAL THR LEU ILE SER PHE GLY ALA PHE SEQRES 9 C 158 VAL ALA LYS HIS LEU LYS THR ILE ASN GLN GLU SER CYS SEQRES 10 C 158 ILE GLU PRO LEU ALA GLU SER ILE THR ASP VAL LEU VAL SEQRES 11 C 158 ARG THR LYS ARG ASP TRP LEU VAL LYS GLN ARG GLY TRP SEQRES 12 C 158 ASP GLY PHE VAL GLU PHE PHE HIS VAL GLU ASP LEU GLU SEQRES 13 C 158 GLY GLY SEQRES 1 D 158 ALA ASP ASP GLU LEU TYR ARG GLN SER LEU GLU ILE ILE SEQRES 2 D 158 SER ARG TYR LEU ARG GLU GLN ALA THR GLY ALA LYS ASP SEQRES 3 D 158 THR LYS PRO MET GLY ARG SER GLY ALA THR SER ARG LYS SEQRES 4 D 158 ALA LEU GLU THR LEU ARG ARG VAL GLY ASP GLY VAL GLN SEQRES 5 D 158 ARG ASN HIS GLU THR ALA PHE GLN GLY MET LEU ARG LYS SEQRES 6 D 158 LEU ASP ILE LYS ASN GLU ASP ASP VAL LYS SER LEU SER SEQRES 7 D 158 ARG VAL MET ILE HIS VAL PHE SER ASP GLY VAL THR ASN SEQRES 8 D 158 TRP GLY ARG ILE VAL THR LEU ILE SER PHE GLY ALA PHE SEQRES 9 D 158 VAL ALA LYS HIS LEU LYS THR ILE ASN GLN GLU SER CYS SEQRES 10 D 158 ILE GLU PRO LEU ALA GLU SER ILE THR ASP VAL LEU VAL SEQRES 11 D 158 ARG THR LYS ARG ASP TRP LEU VAL LYS GLN ARG GLY TRP SEQRES 12 D 158 ASP GLY PHE VAL GLU PHE PHE HIS VAL GLU ASP LEU GLU SEQRES 13 D 158 GLY GLY HET ECY A 400 46 HET ECY B 400 46 HET ECY C 400 46 HET ECY D 400 46 HETNAM ECY 3-({11-[3-(4-CHLORO-3,5-DIMETHYLPHENOXY)PROPYL]-1-OXO- HETNAM 2 ECY 7-(1,3,5-TRIMETHYL-1H-PYRAZOL-4-YL)-4,5-DIHYDRO-1H-[1, HETNAM 3 ECY 4]DIAZEPINO[1,2-A]INDOL-2(3H)-YL}METHYL)BENZOIC ACID FORMUL 5 ECY 4(C37 H39 CL N4 O4) FORMUL 9 HOH *24(H2 O) HELIX 1 AA1 GLU A 173 GLY A 192 1 20 HELIX 2 AA2 SER A 202 HIS A 224 1 23 HELIX 3 AA3 HIS A 224 ASP A 236 1 13 HELIX 4 AA4 ASN A 239 ASP A 256 1 18 HELIX 5 AA5 ASN A 260 ILE A 281 1 22 HELIX 6 AA6 GLN A 283 SER A 285 5 3 HELIX 7 AA7 CYS A 286 GLN A 309 1 24 HELIX 8 AA8 GLY A 311 PHE A 319 1 9 HELIX 9 AA9 LEU B 174 GLY B 192 1 19 HELIX 10 AB1 SER B 202 HIS B 224 1 23 HELIX 11 AB2 HIS B 224 ASP B 236 1 13 HELIX 12 AB3 ASN B 239 LYS B 244 1 6 HELIX 13 AB4 LEU B 246 ASP B 256 1 11 HELIX 14 AB5 ASN B 260 ILE B 281 1 22 HELIX 15 AB6 GLN B 283 SER B 285 5 3 HELIX 16 AB7 CYS B 286 GLN B 309 1 24 HELIX 17 AB8 ARG B 310 PHE B 319 1 10 HELIX 18 AB9 GLU C 173 GLY C 192 1 20 HELIX 19 AC1 SER C 202 HIS C 224 1 23 HELIX 20 AC2 HIS C 224 ASP C 236 1 13 HELIX 21 AC3 ASN C 239 LYS C 244 1 6 HELIX 22 AC4 LEU C 246 ASP C 256 1 11 HELIX 23 AC5 ASN C 260 ILE C 281 1 22 HELIX 24 AC6 GLN C 283 SER C 285 5 3 HELIX 25 AC7 CYS C 286 GLN C 309 1 24 HELIX 26 AC8 ARG C 310 PHE C 319 1 10 HELIX 27 AC9 LEU D 174 GLY D 192 1 19 HELIX 28 AD1 SER D 202 HIS D 224 1 23 HELIX 29 AD2 HIS D 224 ASP D 236 1 13 HELIX 30 AD3 ASN D 239 LYS D 244 1 6 HELIX 31 AD4 LEU D 246 ASP D 256 1 11 HELIX 32 AD5 ASN D 260 ILE D 281 1 22 HELIX 33 AD6 GLN D 283 SER D 285 5 3 HELIX 34 AD7 CYS D 286 GLN D 309 1 24 HELIX 35 AD8 ARG D 310 PHE D 319 1 10 SITE 1 AC1 10 HIS A 224 ALA A 227 PHE A 228 LEU A 246 SITE 2 AC1 10 MET A 250 VAL A 253 ARG A 263 LEU A 267 SITE 3 AC1 10 PHE A 270 GLY A 271 SITE 1 AC2 11 ALA B 227 PHE B 228 LEU B 246 MET B 250 SITE 2 AC2 11 ASN B 260 GLY B 262 ARG B 263 THR B 266 SITE 3 AC2 11 LEU B 267 PHE B 270 GLY B 271 SITE 1 AC3 12 HIS B 252 HIS C 224 ALA C 227 PHE C 228 SITE 2 AC3 12 LEU C 246 MET C 250 ASN C 260 GLY C 262 SITE 3 AC3 12 ARG C 263 THR C 266 LEU C 267 PHE C 270 SITE 1 AC4 13 ALA D 227 PHE D 228 LEU D 246 MET D 250 SITE 2 AC4 13 VAL D 253 PHE D 254 GLY D 262 ARG D 263 SITE 3 AC4 13 THR D 266 LEU D 267 PHE D 270 GLY D 271 SITE 4 AC4 13 ILE D 294 CRYST1 39.284 134.369 96.561 90.00 90.04 90.00 P 1 21 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.025456 0.000000 0.000016 0.00000 SCALE2 0.000000 0.007442 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010356 0.00000